Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'
- 1 February 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Oncology
- Vol. 6 (2), E1
- https://doi.org/10.1038/ncponc1317
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Intermittent androgen blockade should be regarded as standard therapy in prostate cancerNature Clinical Practice Oncology, 2008
- The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer—Survival or Death?Journal of Clinical Oncology, 2008
- Stopping Treatment Can Reverse Acquired Resistance to LetrozoleCancer Research, 2008
- A highly epothilone B–resistant A549 cell line with mutations in tubulin that confer drug dependenceMolecular Cancer Therapeutics, 2005
- Androgen Causes Growth Suppression and Reversion of Androgen-Independent Prostate Cancer Xenografts to an Androgen-Stimulated Phenotype in Athymic MiceCancer Research, 2005
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.JCI Insight, 1997
- Novel nucleolar and nuclear morphology in a vincristine-dependent human leukemia cell line (L100)Experimental Cell Research, 1992
- Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin.The Journal of cell biology, 1986
- Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division.The Journal of cell biology, 1983